Promising results have been observed in phase II, an adaptively randomized I-SPY2 trial combining pembrolizumab, an anti-PD-1 antibody, and taxane- and anthracycline-based neoadjuvant chemotherapies for high-risk stage II/III breast cancer. This evidence concerns the gene PDCD1 and breast cancer.